Weekly paclitaxel in heavily pretreated ovarian cancer patients: Does this treatment still provide further advantages?

Gianmaria Miolo, Ettore Bidoli, Davide Lombardi, Davide Adriano Santeufemia, Giampiero Capobianco, Francesco Dessole, Simona Scalone, Simon Spazzapan, Roberto Sorio, Gianna Tabaro, Andrea Veronesi

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists. Methods Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m2/week paclitaxel regimen. Results The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m2/week and in those with progressive disease 49.7 mg/m2/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p <0.001) and 15.10 (p = 0.0001), respectively. Conclusions Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.

Original languageEnglish
Pages (from-to)499-503
Number of pages5
JournalArchives of Gynecology and Obstetrics
Volume285
Issue number2
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Chemotherapy
  • Dose density
  • Ovarian carcinoma
  • Weekly paclitaxel

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Weekly paclitaxel in heavily pretreated ovarian cancer patients: Does this treatment still provide further advantages?'. Together they form a unique fingerprint.

  • Cite this